These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10972520)

  • 1. The LHRH antagonist cetrorelix: a review.
    Reissmann T; Schally AV; Bouchard P; Riethmiiller H; Engel J
    Hum Reprod Update; 2000; 6(4):322-31. PubMed ID: 10972520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
    Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
    Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GnRH antagonist].
    Yano T; Taketani Y
    Nihon Rinsho; 2001 Jan; 59 Suppl 1():133-8. PubMed ID: 11235152
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.
    Verschraegen CF; Westphalen S; Hu W; Loyer E; Kudelka A; Völker P; Kavanagh J; Steger M; Schulz KD; Emons G
    Gynecol Oncol; 2003 Sep; 90(3):552-9. PubMed ID: 13678723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea.
    Berardelli R; Gianotti L; Karamouzis I; Picu A; Giordano R; D'Angelo V; Zinnà D; Lanfranco F; Ghigo E; Arvat E
    Gynecol Endocrinol; 2011 Oct; 27(10):753-8. PubMed ID: 21204607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
    Tur-Kaspa I; Ezcurra D
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1323-36. PubMed ID: 19761413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men.
    Behre HM; Kliesch S; Pühse G; Reissmann T; Nieschlag E
    J Clin Endocrinol Metab; 1997 May; 82(5):1403-8. PubMed ID: 9141524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Pinski J; Vadillo-Buenfil M; Groot K
    Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2398-402. PubMed ID: 8637885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
    Horvath JE; Toller GL; Schally AV; Bajo AM; Groot K
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4996-5001. PubMed ID: 15044692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy.
    Msaouel P; Diamanti E; Tzanela M; Koutsilieris M
    Expert Opin Emerg Drugs; 2007 May; 12(2):285-99. PubMed ID: 17604502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compensatory response of the luteinizing-hormone (LH)-releasing hormone (LHRH)/LH pulse generator after administration of a potent LHRH antagonist in the ram.
    Lincoln GA; Fraser HM
    Endocrinology; 1987 Jun; 120(6):2245-50. PubMed ID: 3032581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
    Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Cortez-Morales A; Fuentes-Garcia M; Cardenas-Cornejo I; Comaru-Schally AM; Schally AV
    Urology; 1995 Feb; 45(2):275-81. PubMed ID: 7531902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
    Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar SS; Schally AV
    Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers.
    Pechstein B; Nagaraja NV; Hermann R; Romeis P; Locher M; Derendorf H
    J Clin Pharmacol; 2000 Mar; 40(3):266-74. PubMed ID: 10709155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM; Klein B; Steinmeyer E; McGregor GP; Voigt K; Nieschlag E
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.